1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 40 pages

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Circadian Rhythm Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Circadian Rhythm Sleep Disorders. Circadian Rhythm Sleep Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Circadian Rhythm Sleep Disorders.
- A review of the Circadian Rhythm Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Circadian Rhythm Sleep Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Circadian Rhythm Sleep Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Circadian Rhythm Sleep Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Circadian Rhythm Sleep Disorders Overview 6
Therapeutics Development 7
Pipeline Products for Circadian Rhythm Sleep Disorders - Overview 7
Pipeline Products for Circadian Rhythm Sleep Disorders - Comparative Analysis 8
Circadian Rhythm Sleep Disorders - Therapeutics under Development by Companies 9
Circadian Rhythm Sleep Disorders - Therapeutics under Investigation by Universities/Institutes 10
Circadian Rhythm Sleep Disorders - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Circadian Rhythm Sleep Disorders - Products under Development by Companies 13
Circadian Rhythm Sleep Disorders - Products under Investigation by Universities/Institutes 14
Circadian Rhythm Sleep Disorders - Companies Involved in Therapeutics Development 15
Pfizer Inc. 15
Neurim Pharmaceuticals Ltd 16
Orphagen Pharmaceuticals, Inc. 17
Omeros Corporation 18
Circadian Rhythm Sleep Disorders - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Assessment by Therapeutic Class 27
Drug Profiles 29
melatonin - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Fibrate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
PF-4800467 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
OPN4 Antagonist - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Drug For Circadian Rhythm Sleep Disorders - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Circadian Rhythm Sleep Disorders - Recent Pipeline Updates 35
Circadian Rhythm Sleep Disorders - Dormant Projects 36
Circadian Rhythm Sleep Disorders - Product Development Milestones 37
Featured News and Press Releases 37
May 30, 2013: Vanda Pharma To Present Tasimelteon Non-24 Phase III Data At Two Medical Meetings 37
Mar 08, 2011: Vanda Pharmaceuticals Receives Orphan Drug Designation In Europe For Tasimelteon 37
Aug 26, 2010: Vanda Initiates Phase III Clinical Study Aimed At Resetting Body Clock 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40



List of Tables

Number of Products under Development for Circadian Rhythm Sleep Disorders, H2 2013 7
Number of Products under Development for Circadian Rhythm Sleep Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Circadian Rhythm Sleep Disorders - Pipeline by Pfizer Inc., H2 2013 15
Circadian Rhythm Sleep Disorders - Pipeline by Neurim Pharmaceuticals Ltd, H2 2013 16
Circadian Rhythm Sleep Disorders - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2013 17
Circadian Rhythm Sleep Disorders - Pipeline by Omeros Corporation, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 24
Number of Products by Stage and Route of Administration, H2 2013 25
Number of Products by Stage and Molecule Type, H2 2013 26
Number of Products by Stage and Therapeutic Class, H2 2013 28
Circadian Rhythm Sleep Disorders Therapeutics - Recent Pipeline Updates, H2 2013 35
Circadian Rhythm Sleep Disorders - Dormant Projects, H2 2013 36



List of Figures

Number of Products under Development for Circadian Rhythm Sleep Disorders, H2 2013 7
Number of Products under Development for Circadian Rhythm Sleep Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Stage and Top 10 Molecule Type, H2 2013 26
Number of Products by Top 10 Therapeutic Class, H2 2013 27
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 28



Companies Mentioned

Pfizer Inc.
Neurim Pharmaceuticals Ltd
Orphagen Pharmaceuticals, Inc.
Omeros Corporation

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, ...

Insomnia - Pipeline Review, H2 2016

Insomnia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Insomnia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Insomnia – Pipeline Review, H2 2016, provides an overview of the Insomnia ...

Insomnia - Pipeline Review, H1 2016

Insomnia - Pipeline Review, H1 2016

  • $ 2000
  • Company report
  • May 2016
  • by Global Markets Direct

Insomnia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2016’, provides an overview of the Insomnia pipeline landscape. The report provides comprehensive ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.